Abstract
Impaired endothelial function is recognised as one of the earliest events of atherogenesis. Endothelium-dependent vasomotion has been the principal method to assess endothelial function. In this article, we will discuss the clinical value of the different techniques to evaluate endothelium-dependent vasomotion. To date, there seems not to be a simple and reliably endothelial function test to identify asymptomatic subjects at increased risk for cardiovascular disease in clinical practice. Recent studies indicate that pharmacological interventions, in particular with ACE-inhibitors and statins, might improve endothelial function. However, there is no solid evidence that improvement of endothelial function is a necessity for the observed reduction in cardiovascular events by these compounds. Overall, at this moment, there is no place in clinical practice for the use of endothelial function as a method for risk assessment or target of pharmacological interventions.
| Original language | English |
|---|---|
| Pages (from-to) | 125-40 |
| Number of pages | 16 |
| Journal | Vascular pharmacology |
| Volume | 42 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Feb 2005 |
| Externally published | Yes |
Keywords
- Animals
- Cardiovascular Diseases/drug therapy
- Endothelium, Vascular/drug effects
- Glyceraldehyde-3-Phosphate Dehydrogenases/pharmacology
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
- Peptide Fragments/pharmacology
- Vasomotor System/drug effects